$7.40
1.86%
Nasdaq, Sep 26, 10:00 pm CET
ISIN
US0887861088
Symbol
BCYC

Bicycle Therapeutics Plc Stock price

$7.40
+0.41 5.87% 1M
-1.33 15.23% 6M
-6.60 47.14% YTD
-15.92 68.27% 1Y
-15.02 66.99% 3Y
-12.29 62.42% 5Y
-6.60 47.14% 10Y
-6.60 47.14% 20Y
Nasdaq, Closing price Fri, Sep 26 2025
-0.14 1.86%
ISIN
US0887861088
Symbol
BCYC
Industry

Key metrics

Basic
Market capitalization
$522.6m
Enterprise Value
$-197.9m
Net debt
positive
Cash
$721.5m
Shares outstanding
69.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
27.1 | 18.1
EV/Sales
negative | negative
EV/FCF
0.9
P/B
0.8
Financial Health
Equity Ratio
82.9%
Return on Equity
-21.3%
ROCE
-37.7%
ROIC
-357.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$19.3m | $28.9m
EBITDA
$-277.2m | $-296.5m
EBIT
$-284.4m | $-323.2m
Net Income
$-242.4m | $-295.7m
Free Cash Flow
$-210.3m
Growth (TTM | estimate)
Revenue
-51.3% | -18.2%
EBITDA
-57.2% | -46.8%
EBIT
-55.4% | -54.5%
Net Income
-46.6% | -75.0%
Free Cash Flow
-27.6%
Margin (TTM | estimate)
Gross
-
EBITDA
-1,437.9% | -1,027.2%
EBIT
-1,475.3%
Net
-1,257.0% | -1,024.4%
Free Cash Flow
-1,090.7%
More
EPS
$-3.5
FCF per Share
$-3.0
Short interest
3.8%
Employees
305
Rev per Employee
$120.0k
Show more

Is Bicycle Therapeutics Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Bicycle Therapeutics Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

20 Analysts have issued a Bicycle Therapeutics Plc forecast:

16x Buy
80%
4x Hold
20%

Analyst Opinions

20 Analysts have issued a Bicycle Therapeutics Plc forecast:

Buy
80%
Hold
20%

Financial data from Bicycle Therapeutics Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
19 19
51% 51%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 79 79
25% 25%
410%
- Research and Development Expense 228 228
43% 43%
1,183%
-277 -277
57% 57%
-1,438%
- Depreciation and Amortization 7.21 7.21
9% 9%
37%
EBIT (Operating Income) EBIT -284 -284
55% 55%
-1,475%
Net Profit -242 -242
47% 47%
-1,257%

In millions USD.

Don't miss a Thing! We will send you all news about Bicycle Therapeutics Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bicycle Therapeutics Plc Stock News

Neutral
Seeking Alpha
20 days ago
Bicycle Therapeutics plc (NASDAQ:BCYC ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Kevin Lee - CEO & Executive Director Jennifer Perry - Chief Strategy Officer & Head of Commercial Alethia Young - Chief Financial Officer Conference Call Participants Maxwell Skor - Morgan Stanley, Research Division Presentation Maxwell Skor Equity A...
Neutral
Business Wire
21 days ago
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the appointments of Roger Dansey, M.D., and Hervé Hoppenot to the company's Board of Directors. "We are thrilled to welcome Roger and Hervé to our...
Neutral
The Motley Fool
about 2 months ago
Bicycle (BCYC) Q2 Revenue Falls 69%
More Bicycle Therapeutics Plc News

Company Profile

Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display screening platform to identify bicycles. Its portfolio includes internal product candidates that are directed to oncology applications. The company was founded by Gregory Winter, John Tite, and Christian Heinis in 2009 and is headquartered in Cambridge, the United Kingdom.

Head office United Kingdom
CEO Kevin Lee
Employees 305
Founded 2009
Website www.bicycletherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today